Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination
of both is better to treat scarring of the lung caused by Systemic Sclerosis.